Docetaxel-Ebewe

DRUG3 trials

Sponsors

Bristol-Myers Squibb International Corporation, Bristol-Myers Squibb Services Unlimited Company

Conditions

Early Stage Non-Small Cell Lung Cancer (NSCLC)Male and female participants ≥ 18 years of age with advanced or metastatic cancersResectable Stage II-IIIB Non-small cell lung cancer

Phase 1

A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors

RecruitingCTIS2023-503651-10-00

Bristol-Myers Squibb Services Unlimited CompanyMale and female participants ≥ 18 years of age with advanced or metastatic cancers

Start: 2022-05-17Target: 163Updated: 2025-12-04

Phase 3

Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC

CompletedCTIS2022-501360-18-00

Bristol-Myers Squibb International CorporationEarly Stage Non-Small Cell Lung Cancer (NSCLC)

Start: 2017-03-15End: 2024-12-03Target: 194Updated: 2024-12-03

A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer (CheckMate 77T, CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 77T)

Active, not recruitingCTIS2022-502658-15-00

Bristol-Myers Squibb Services Unlimited CompanyResectable Stage II-IIIB Non-small cell lung cancer

Start: 2019-09-22Target: 252Updated: 2025-10-08